组蛋白去乙酰化酶抑制剂在抗病毒药物研究中的进展

Research progress of histone deacetylases inhibitors in antiviral drugs discovery

组蛋白去乙酰化酶(HDACs)是一类关键的表观遗传修饰酶。目前,已经有5个小分子HDACs抑制剂获批上市,主要应用于抗肿瘤领域。近年来,有关HDACs抑制剂在抗病毒方面的研究越来越多。本文从药物化学的视角,按艾滋病毒(HIV-1)、新型冠状病毒(SARS-CoV-2)、EB病毒(EBV)和其他病毒等分类归纳,系统总结了近年来HDACs抑制剂在辅助抗病毒领域的进展。本综述旨在帮助药学工作者了解掌握HDACs抑制剂在抗病毒方面的最新成果,展望HDACs抑制剂在抗病毒领域应用的挑战和前景。

Histone deacetylases(HDACs) are a class of key enzymes that regulate epigenetics. There are 5small-molecule HDACs inhibitors having been approved for anti-cancer therapy on the market. In recent years,there have been more and more studies on the antiviral aspects of HDACs inhibitors. This article classifies viruses into human immunodeficiency virus 1(HIV-1), new coronavirus(SARS-CoV-2), Epstein-Barr virus(EBV) and other viruses, systematically summarizes the recent advances of antiviral effects of the HDACs inhibitors from the perspective of medicinal chemistry. This review aims to provide the researchers the convenience of accessing the latest advances of the antiviral effects of HDACs inhibitors, and to analyze the challenges and prospects of this field in future drug discovery.